On the heels of President Donald Trump’s Monday announcement of an executive order that will slash prescription drug prices in the U.S., the spotlight is on current costs and how much Americans could save. The president’s order calls for “most favored nations drug pricing” — which means “the lowest price paid for a drug in … Read more
Nature Communications, Published online: 13 May 2025; doi:10.1038/s41467-025-59485-9 Myostatin and activin A are the two primary negative regulators of muscle mass. Blocking these circulating ligands during GLP-1 therapy induces improved body composition through preservation of lean mass and enhanced fat mass loss in obese primates.
The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published, examining their ability to reduce weight and waist circumference. And one clearly comes out on top. Continue Reading Category: Obesity, Illnesses and conditions, Body & Mind Tags: GLP-1 receptor agonists, Obesity, Weight Loss, clinical trials, Weill Cornell Medicine
This academic paper examines whether tailoring anti-obesity medication based on specific patient characteristics, or “phenotypes,” improves weight loss outcomes compared to standard treatment. Researchers classified individuals with obesity into four main phenotypes: “hungry brain” (abnormal satiation), “emotional hunger” (hedonic eating), “hungry gut” (abnormal satiety), and “slow burn” (decreased metabolic rate). A clinical trial showed that the phenotype-guided approach resulted in significantly greater weight loss and … Read more
Ever since the pharmaceutical company Novo Nordisk realized that GLP-1 drugs were useful for more than diabetes, doctors and researchers have struggled to answer a deceptively simple question: Who should be taking them? The medications are highly effective at inducing weight loss, and most Americans are overweight or have obesity. But GLP-1s are also expensive, … Read more
Children who are living with severe obesity are more likely to experience a clinically relevant change in BMI when GLP-1 agonist drugs form part of their treatment, new research being presented at year’s European Congress on Obesity (ECO 2025) suggests.
What You Should Know: – Veradigm, a provider of healthcare data and technology solutions, today announced a significant advancement in the application of artificial intelligence (AI) to scale the generation of real-world evidence (RWE) for the increasingly prevalent GLP-1 receptor agonists (GLP-1 RAs), including widely used medications like semaglutide and tirzepatide. By deploying AI algorithms … Read more
(MedPage Today) — Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial. By week 72, participants on the dual GIP/GLP-1 receptor agonist tirzepatide lost 20.2% of body weight…
President Donald Trump signed an executive order May 12 directing drugmakers to sell medicines in the U.S. at prices similar to those offered in other wealthy countries, or face penalties and enforcement actions. The move tasks HHS Secretary Robert F. Kennedy Jr. with setting target prices to bring U.S. drug costs “in line with comparably … Read more
For years, researchers had been searching for hormones that promote insulin secretion. These hormones, known as incretins, could be the key to helping treat type 2 diabetes (T2D). In the 1980s, glucagon-like peptide-1 (GLP-1) was found to be an incretin secreted by L-cells in the small intestine and to inhibit glucagon secretion. However, because of … Read more